Home › Business › Pharmaceuticals News

Latest Stories

Pfizer arthritis drug advances in its FDA approval process

 May 10, 2012

Pfizer Inc. announced today that an advisory committee of the U.S. Food and Drug Administration has recommended regulatory approval of the company's experimental pill for the treatment of rheumatoid arthritis.

The drug, tofacitinib, was...

Amarin reports 'positive' quarter

 May 10, 2012

Amarin Corp. plc, which has research headquarters in Groton, reported a first-quarter loss of $88.3 million compared with an $18.3 million profit for the same period last year.

The loss was a little more than analysts expected.

But...

FDA panel to take look at Pfizer's new RA pill

 May 9, 2012

A key drug in Pfizer Inc.'s pipeline will be scrutinized by an advisory panel starting today after a U.S. Food and Drug Administration staff report raised questions about patients' increased risk of lymphoma, infections and other serious...

FDA panel backs Pfizer drug

 May 9, 2012

Pfizer Inc. announced today that an advisory committee of the U.S. Food and Drug Administration has recommended regulatory approval of the company's experimental pill for the treatment of rheumatoid arthritis.

Pfizer vice president Kerins to leave company

 May 8, 2012

Ray Kerins, vice president of worldwide communications at Pfizer Inc., is one of several officials at the drug giant to see the continued effects of the company's downsizing.

Pfizer halts late-stage Lyrica study

 May 5, 2012

New York - Pfizer halted a late-stage study of its second-best selling drug, Lyrica, as a possible treatment for a nerve pain in HIV patients.

The world's largest drugmaker said Friday it was studying the drug in patients with HIV...

Pfizer's Read No. 2 paid pharma exec

 May 5, 2012

Ian Read, chief executive of Pfizer Inc., rose to No. 2 on the list of most highly compensated drug company executives last year, raking in $25 million in base pay, bonuses and stock awards.

FiercePharma's annual rankings placed William...

Celebrex settlement cuts into Pfizer profits

 May 2, 2012

Pfizer Inc.'s settlement of a lawsuit filed by Brigham Young University over the development of pain medication Celebrex cut into first-quarter profits, the company reported Tuesday.

Pfizer, which has its largest worldwide research site in...

Pfizer profits down 19 percent

 May 1, 2012

Pfizer Inc.’s first full quarter without a patent-protected Lipitor cholesterol drug in its war chest proved dicey when the company released today first-quarter financials  that showed profits falling 19 percent from the same...

Officials hope to limit Pfizer demolition

 April 27, 2012

Pfizer Inc.’s decision to tear down one of the five Groton campus buildings it has been trying to sell led town and city officials Friday to offer to help market the properties.

Avery Point opens doors to invite entrepreneurs

 April 27, 2012

Groton - Kenneth C. Waterman, chief executive and founder of FreeThink Technologies Inc., was one of several entrepreneurs at the University of Connecticut at Avery Point who were dreaming Thursday of moving their fledgling companies to...

Toni Hoover, leader of Pfizer locally, will leave in May

 April 24, 2012

Toni Hoover, a Pfizer Inc. senior vice president who has been local site leader for the pharmaceutical giant during one of its most tumultuous periods, will be leaving the company, Pfizer announced Tuesday.

Pfizer bows out of Enbrel marketing

 April 21, 2012

Pfizer Inc. and Amgen are winding down their marketing agreement for the anti-inflammatory drug Enbrel, according to The Wall Street Journal.

Amgen is taking over marketing duties for the United States and Puerto Rico starting July 23,...

Pfizer is tops among drug companies for consumer ad spending

 April 19, 2012

Pfizer Inc. far surpassed any other drugmaker in direct-to-consumer advertising last year, spending more than $220 million on its flagging Lipitor franchise and nearly $900 million overall.

Ex-Pfizer CEO McKinnell takes over as chairman of Optimer Pharmaceuticals

 April 16, 2012

Hank McKinnell, who engineered two megamergers as chairman and chief executive of Pfizer Inc. before walking away with more than $100 million when he retired in 2006, has taken over as chairman of Optimer Pharmaceuticals Inc. just a few...

Pfizer's next layoff packages shrink

 April 10, 2012

Pfizer Inc. personnel being laid off at the company's Groton laboratories after May 14 will receive less money than previous waves of departing workers have received.

Pfizer, at the tail end of a planned 1,100 layoffs locally, said in a...

Researchers applaud antibiotics bill

 April 6, 2012

New Haven - A bill co-sponsored by U.S. Sen. Richard Blumenthal to promote antibiotics research that could reduce the nearly 100,000 worldwide deaths each year from drug-resistant infections received a warm welcome Thursday during a...

Prescription drug spending stays nearly flat

 April 5, 2012

Spending on prescription drugs in the U.S. was nearly flat in 2011 at $320 billion, held down by senior citizens and others reducing use of medicines and other health care and by greater use of cheaper generic pills.

Last year, spending on...

Prospect of breakup has Pfizer stock riding to a four-year high

 April 2, 2012

Pfizer Inc. chief executive Ian Read signals an intention not only to sell off the drug firm's animal health and nutrition business but to consider separating the generics and brand-name pharmaceuticals units as well.

Whistleblower now reluctant biotech safety spokeswoman

 April 1, 2012

Former Pfizer Inc. molecular biologist Becky McClain calls herself a "reluctant activist" now that she has become a national spokeswoman for biotech safety after winning a $1.37 million judgment two years ago against her former employer.

Report highlights CT clinical trials

 March 30, 2012

Eastern Connecticut Hematology & Oncology and Comprehensive Psychiatric Care, both in Norwich, are among the 180 medical facilities in the state currently conducting clinical drug trials, according to a report released Thursday by the...

Columnists

Popular on theday.com

Interact